Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
NCT ID: NCT03389438
Last Updated: 2021-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
6 participants
INTERVENTIONAL
2018-02-26
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will recruit patients with pathologically and radiographically confirmed metastatic bladder urothelial carcinoma that the efficacy is evaluated as partial response (PR) or complete response (CR) after 4 cycles of the standard first-line gemcitabine plus cisplatin chemotherapy. Patients must have adequate hematologic and end-organ function, performance status and no contraindications to receive autologous Tcm cells immunotherapy. All participants will be treated with standard first-line gemcitabine plus cisplatin chemotherapy before enrolment.
This clinical trial was designed with a single-center randomized controlled trial. The study will recruit 56 patients that will be divided into treatment group and control group as 1:1 according to the randomization. Patients of treatment group will be treated with twice autologous Tcm cells immunotherapy after chemotherapy. These patients will be infused in 2-4×10\^9 cells/100 ml after chemotherapy for 1 month, then cells will be infused as the same dose after another month. All patients will be followed up with hospital visits and telephone interviews to second-line treatment for disease progression. The observation period of patients is 24 months.
The objective of the study is to evaluate the clinical efficacy and safety of autologous Tcm cells immunotherapy in patients with metastatic bladder epithelial carcinoma treated with first-line gemcitabine plus cisplatin according to the progression-free survival (PFS) and overall survival (OS) of these patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
No intervention arm: participants who were treated with no autologous Tcm cells immunotherapy.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental arm
Participants who were treated with autologous Tcm cells immunotherapy.
autologous Tcm cells immunotherapy
Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
No intervention arm
Participants who were treated with no autologous Tcm cells immunotherapy.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous Tcm cells immunotherapy
Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with pathologically and radiographically confirmed metastatic bladder urothelial carcinoma that the efficacy was evaluated as PR or CR after 4 cycles of the standard first-line gemcitabine plus cisplatin
3. 18-75 years old
4. CR or PR confirmed by independent radiological examination.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Adequate hematologic and end-organ function:
Hemoglobin ≥ 9.0g/dl, Absolute neutrophil count (ANC) \> 1,500/mm3, platelets ≥ 50,000/ul Total bilirubin (TBIL) ≤ 2mg/dl, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 the upper limit of normal (ULN) for the institution, Alkaline phosphatase (ALP) ≤ 4 the upper limit of ULN, Prothrombin time (PT) \> 50% or prothrombin time-international normalized ratio (PT-INR) \< 2.3, Serum creatinine (CREA) ≤ 1.5 the upper limit of ULN.
7. Qualified scanning (CT or MRI) was performed in 4 weeks before the study.
Exclusion Criteria
2. Subjects with pathologically bladder urothelial carcinoma of mixed other pathological types such as squamous differentiation or sarcoma are not allowed.
3. Prior radiation therapy to the bladder
4. Significant cardiovascular disease:
Evidence of NYHA (New York Heart Association) functional class III or IV heart disease.
Unstable coronary artery disease (CAD) is not allowed, while Myocardial Infarction (MI) 6 months of starting study is allowed.
Cardiac arrhythmias requiring antiarrhythmic drugs except β-blockers or digoxin are not allowed.
Uncontrolled hypertension.
5. History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
6. Severe infection (NCI CTCAE Version 3.0 grade \> 2).
7. Subjects with epilepsy requiring steroid or antiepileptic drugs.
8. History of allotransplantation.
9. History or any evidence of hemorrhage.
10. Subjects undergoing renal dialysis.
11. Prior or undergoing cancers that primary sites are different from the cancer of this study. Exceptions to this are Cervical carcinoma in situ (CIS), Cured basal cell carcinoma and Cured cancers over 3 years before the study.
12. Ascites that is not controlled by diuretic treatment.
13. History of encephalopathy.
14. Subjects with gastrointestinal hemorrhage in 30 days before the study.
15. Subjects with history of esophageal variceal hemorrhage and it is no effective treatment to prevent the recurrence of hemorrhage.
16. Major surgery was performed in 4 weeks before the study.
17. Autologous bone marrow transplantation (ABMT) in 4 weeks before the study.
18. Concurrent treatment on another clinical trial or treatment on another clinical trial in 4 weeks before the study.
19. Pregnancy or breast-feeding.
20. There are drug abuse, medical treatment, mental illness and social disorders that would interfere with subjects' participation, or confound the results of the trial.
21. Any condition that would interfere with or endanger the safety and compliance of subjects.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Newish Technology (Beijing) Co., Ltd.
INDUSTRY
Beijing Huanxing Cancer Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dong Wang, Master
Role: PRINCIPAL_INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Linjun Hu
Role: STUDY_CHAIR
Beijing Huanxing Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huanxing ward, Cancer Hospital Chinese Academy of Medical Sciences
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BeijingHCH
Identifier Type: -
Identifier Source: org_study_id